Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
Rhea-AI Summary
Aspira Women's Health (Nasdaq: AWH) has scheduled its Q3 2024 earnings release for Thursday, November 14, 2024. The company will discuss financial results for the three and nine months ended September 30, 2024. Management will host a conference call at 8:30 am ET to present financial results and provide a corporate update. The call will be accessible via toll-free number (877-545-0320) and international number (973-528-0002) with access code 436613. A webcast replay will be available on the company's Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – AWH
On the day this news was published, AWH declined 1.56%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Management to Announce Earnings Results and hold a call at 8:30 am ET
AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows:
| Conference Call & Webcast Details: | |
| Date: | Thursday, November 14, 2024 |
| Time: | 8:30 am ET |
| Toll Free: | 877-545-0320 |
| International: | 973-528-0002 |
| Access Code: | 436613 |
| Webcast: | Registration Link |
A replay of the webcast will also be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Investor Relations Contact:
Jamie Sullivan
Director of Corporate Communications
Aspira Women’s Health
Investors@aspirawh.com
FAQ
When will Aspira Women's Health (AWH) report Q3 2024 earnings?
What time is Aspira Women's Health (AWH) Q3 2024 earnings call?
How can I access Aspira Women's Health (AWH) Q3 2024 earnings call?
What period will Aspira Women's Health (AWH) Q3 2024 earnings cover?
